PE20240124A1 - Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma - Google Patents
Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la mismaInfo
- Publication number
- PE20240124A1 PE20240124A1 PE2023001495A PE2023001495A PE20240124A1 PE 20240124 A1 PE20240124 A1 PE 20240124A1 PE 2023001495 A PE2023001495 A PE 2023001495A PE 2023001495 A PE2023001495 A PE 2023001495A PE 20240124 A1 PE20240124 A1 PE 20240124A1
- Authority
- PE
- Peru
- Prior art keywords
- preparation
- crystalline form
- receptor agonist
- melanocortin receptor
- agonist compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 229940117029 Melanocortin receptor agonist Drugs 0.000 title 1
- 239000000336 melanocortin receptor agonist Substances 0.000 title 1
- 102000001796 Melanocortin 4 receptors Human genes 0.000 abstract 2
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 abstract 2
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940047889 isobutyramide Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A LA FORMA CRISTALINA II DEL HIDRATO DE CLORHIDRATO DE N-((3S,5S)-1-((3S,4R)-1-(TER-BUTIL)-4-(4-CLOROFENIL)PIRROLIDIN-3-CARBONIL)-5-(MORFOLIN-4-CARBONIL)-PIRROLIDIN-3-IL)-N-((1S,4R)-4-METILCICLOHEXIL)ISOBUTIRAMIDA CUYO PATRON DE DIFRACCION DE POLVO DE RAYOS X PRESENTA PICOS CARACTERISTICOS CON LOS SIGUIENTES ANGULOS DE DIFRACCION (VALORES 2THETA) DE: 7.77±0.2°, 9.82±0.2°, 10.50±0.2°, 11.37±0.2°, 12.36±0.2°, 15.17±0.2°, 15.46±0.2°, 15.88±0.2°, 16.75±0.2°, 17.59±0.2°, 17.93±0.2°, 18.33±0.2°, 19.64±0.2°, 20.19±0.2°, 21.19±0.2°, 21.71±0.2°, 23.29±0.2°, 23.58±0.2°, 24.42±0.2°, 25.07±0.2°, 25.63±0.2°, 26.31±0.2°, 27.17±0.2°, 27.52±0.2° Y 28.96±0.2°. TAMBIEN SE REFIERE A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE. DICHO COMPUESTO ES AGONISTA DEL RECEPTOR DE MELANOCORTINA-4 (MC4R) SIENDO UTIL EN EL TRATAMIENTO DE OBESIDAD, DIABETES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200142397 | 2020-10-29 | ||
| PCT/KR2021/015470 WO2022092910A1 (ko) | 2020-10-29 | 2021-10-29 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅱ 및 이의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240124A1 true PE20240124A1 (es) | 2024-01-22 |
Family
ID=81384111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001495A PE20240124A1 (es) | 2020-10-29 | 2021-10-29 | Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230399321A1 (es) |
| EP (1) | EP4219473A4 (es) |
| JP (1) | JP2023548163A (es) |
| KR (2) | KR102672625B1 (es) |
| CN (1) | CN116490497A (es) |
| AU (1) | AU2021371829B2 (es) |
| CA (1) | CA3195432A1 (es) |
| CL (1) | CL2023001224A1 (es) |
| CO (1) | CO2023006517A2 (es) |
| IL (1) | IL302426A (es) |
| MX (1) | MX2023004656A (es) |
| PE (1) | PE20240124A1 (es) |
| WO (1) | WO2022092910A1 (es) |
| ZA (1) | ZA202305595B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI814185B (zh) * | 2020-12-22 | 2023-09-01 | 南韓商Ｌｇ化學股份有限公司 | 黑皮質素受體促效劑化合物之晶型ii及其製備方法 |
| US20240043407A1 (en) * | 2020-12-22 | 2024-02-08 | Lg Chem, Ltd. | Crystalline form i of melanocortin receptor agonist compound and method for preparing same |
| KR20220090458A (ko) * | 2020-12-22 | 2022-06-29 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅲ 및 이의 제조방법 |
| WO2022235104A1 (ko) * | 2021-05-06 | 2022-11-10 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 v 및 이의 제조방법 |
| CA3217198A1 (en) * | 2021-05-07 | 2022-11-10 | Lg Chem, Ltd. | Sulfate crystals of melanocortin receptor agonist compound and method of producing same |
| US20240239769A1 (en) * | 2021-05-07 | 2024-07-18 | Lg Chem, Ltd. | Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000074679A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| US7157463B2 (en) * | 2001-01-23 | 2007-01-02 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
| AR044510A1 (es) | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
| KR100661118B1 (ko) * | 2003-11-12 | 2006-12-26 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
| KR20080007046A (ko) * | 2006-07-14 | 2008-01-17 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
| TWI332501B (en) | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| BR112019016488B1 (pt) | 2017-02-08 | 2022-11-16 | Tilray, Inc | Método e aparato para processamento de cannabis com energia radiante de baixa pressão |
| UA127255C2 (uk) * | 2019-11-07 | 2023-06-21 | Елджі Кем, Лтд. | Агоністи рецептора меланокортину-4 |
-
2021
- 2021-10-29 PE PE2023001495A patent/PE20240124A1/es unknown
- 2021-10-29 AU AU2021371829A patent/AU2021371829B2/en active Active
- 2021-10-29 MX MX2023004656A patent/MX2023004656A/es unknown
- 2021-10-29 US US18/251,101 patent/US20230399321A1/en active Pending
- 2021-10-29 CA CA3195432A patent/CA3195432A1/en active Pending
- 2021-10-29 CN CN202180073241.7A patent/CN116490497A/zh active Pending
- 2021-10-29 KR KR1020210146189A patent/KR102672625B1/ko active IP Right Grant
- 2021-10-29 IL IL302426A patent/IL302426A/en unknown
- 2021-10-29 WO PCT/KR2021/015470 patent/WO2022092910A1/ko active Application Filing
- 2021-10-29 EP EP21886904.8A patent/EP4219473A4/en active Pending
- 2021-10-29 JP JP2023526435A patent/JP2023548163A/ja active Pending
-
2023
- 2023-04-27 CL CL2023001224A patent/CL2023001224A1/es unknown
- 2023-05-17 CO CONC2023/0006517A patent/CO2023006517A2/es unknown
- 2023-05-24 ZA ZA2023/05595A patent/ZA202305595B/en unknown
-
2024
- 2024-05-31 KR KR1020240071409A patent/KR20240085231A/ko active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CA3195432A1 (en) | 2022-05-05 |
| KR102672625B1 (ko) | 2024-06-07 |
| AU2021371829A1 (en) | 2023-06-01 |
| AU2021371829B2 (en) | 2024-01-18 |
| CN116490497A (zh) | 2023-07-25 |
| MX2023004656A (es) | 2023-05-18 |
| IL302426A (en) | 2023-06-01 |
| EP4219473A1 (en) | 2023-08-02 |
| US20230399321A1 (en) | 2023-12-14 |
| ZA202305595B (en) | 2024-09-25 |
| EP4219473A4 (en) | 2024-03-13 |
| KR20240085231A (ko) | 2024-06-14 |
| JP2023548163A (ja) | 2023-11-15 |
| CL2023001224A1 (es) | 2023-11-03 |
| WO2022092910A1 (ko) | 2022-05-05 |
| CO2023006517A2 (es) | 2023-09-08 |
| KR20220057471A (ko) | 2022-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240367A1 (es) | Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20240124A1 (es) | Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20240366A1 (es) | Forma cristalina iii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20240048A1 (es) | Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma | |
| PE20220766A1 (es) | Agonistas de receptor de melanocortina-4 | |
| PE20180160A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
| ATE528005T1 (de) | 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen | |
| EA202090029A1 (ru) | Твердая композиция карипразина для орального введения | |
| CL2008000127A1 (es) | Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos | |
| CL2021001325A1 (es) | Ureas cíclicas. | |
| PE20110684A1 (es) | Agonistas de los receptores de la melanocortina | |
| PE20090912A1 (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
| JP2010514832A5 (es) | ||
| RU2017111590A (ru) | Кристаллические формы 2-(4-(4-этокси-6-оксо-1,6-дигидропиридин-3-ил)-2-фторфенил)-n-(5-(1,1,1-трифтор-2- метилпропан-2-ил)изоксазол-3-ил)ацетамида | |
| AR074632A1 (es) | Compuesto de amidofenoxiindazol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util en el tratamiento de cancer | |
| RS53251B (sr) | Kristali koji sadrže n-[2-dietilamino)etil]-5-[(5-fluoro-2-okso-3h-indol-3-iliden)metil]-2,4-dimetil-1h-pirol-3- karboksamid so jabučne kiseline, procesi za njihovu pripremu i njihovi preparati | |
| RU2016114540A (ru) | Соль азотсодержащего гетероциклического соединения или ее кристаллическая форма, фармацевтическая композиция и ингибитор flt3 | |
| EA201891413A1 (ru) | Фармацевтическая композиция, содержащая безводный дазатиниб | |
| CL2011000795A1 (es) | Compuestos derivados de n-(1,3,4-tiadiazol-2-il) aril/heteroaril-amida, agonistas del receptor de 1-fosfato de esfingosina; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratammiento de enfermedades autoinmunes, inflamatorias cronicas, rechazo de transplantes, dolor, entre otras. | |
| MA43833B1 (fr) | Nouvelle forme cristalline de sel de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine | |
| MX2023003054A (es) | Formas solidas de un inhibidor de cdk4. | |
| SA521422467B1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
| IL313292A (en) | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND TYPE II DIABETES | |
| PH12019500287A1 (en) | Crystals of cyclic amine derivative and pharmaceutical use thereof | |
| CL2020001928A1 (es) | Formas cristalinas del antagonista del receptor cxcr7 ácido (3s,4s)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxílico (1-pirimidin-2-il-ciclopropil)-amida. |